SEQIRUS for SEQIRUS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Supplemental appropriations for COVID-19; FY22 & FY23 Appropriations for Pandemic Influenza and CDC Immunization programs; PDUFA reauthorization
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON New | OMB, Health Division, Program Examiner (2010-2021) |
Health Issues HCR
Department of Defense immunization strategy; CDC immunization programs and policies
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON New | OMB, Health Division, Program Examiner (2010-2021) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.